More intriguingly, BAY-155, a menin molecule inhibitor, inhibited cell growth of BLCA cells both in vitro and in vivo by suppressing the expression of menin, TFAP2C, and β-catenin. Here, TFAP2C is linked to bladder transitional cell carcinoma.